Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Suppression of metastatic organ colonization and antiangiogenic activity of the orally bioavailable lipid raft-targeted alkylphospholipid edelfosine.
Alonso-Pérez V, Hernández V, Calzado MA, Vicente-Blázquez A, Gajate C, Soler-Torronteras R, DeCicco-Skinner K, Sierra A, Mollinedo F. Alonso-Pérez V, et al. Biomed Pharmacother. 2024 Feb;171:116149. doi: 10.1016/j.biopha.2024.116149. Epub 2024 Jan 24. Biomed Pharmacother. 2024. PMID: 38266621 Free article.
The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.
García-Tuñón I, Hernández-Sánchez M, Ordoñez JL, Alonso-Pérez V, Álamo-Quijada M, Benito R, Guerrero C, Hernández-Rivas JM, Sánchez-Martín M. García-Tuñón I, et al. Among authors: alonso perez v. Oncotarget. 2017 Apr 18;8(16):26027-26040. doi: 10.18632/oncotarget.15215. Oncotarget. 2017. PMID: 28212528 Free PMC article.
Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency.
García-Tuñón I, Alonso-Pérez V, Vuelta E, Pérez-Ramos S, Herrero M, Méndez L, Hernández-Sánchez JM, Martín-Izquierdo M, Saldaña R, Sevilla J, Sánchez-Guijo F, Hernández-Rivas JM, Sánchez-Martín M. García-Tuñón I, et al. Among authors: alonso perez v. PLoS One. 2019 May 9;14(5):e0216674. doi: 10.1371/journal.pone.0216674. eCollection 2019. PLoS One. 2019. PMID: 31071190 Free PMC article.
CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia.
Vuelta E, Ordoñez JL, Alonso-Pérez V, Méndez L, Hernández-Carabias P, Saldaña R, Sevilla J, Sebastián E, Muntión S, Sánchez-Guijo F, Hernández-Rivas JM, García-Tuñón I, Sánchez-Martín M. Vuelta E, et al. Among authors: alonso perez v. CRISPR J. 2021 Aug;4(4):519-535. doi: 10.1089/crispr.2021.0009. CRISPR J. 2021. PMID: 34406033
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression.
Quijada-Álamo M, Hernández-Sánchez M, Rodríguez-Vicente AE, Pérez-Carretero C, Rodríguez-Sánchez A, Martín-Izquierdo M, Alonso-Pérez V, García-Tuñón I, Bastida JM, Vidal-Manceñido MJ, Galende J, Aguilar C, Queizán JA, González-Gascón Y Marín I, Hernández-Rivas JÁ, Benito R, Ordóñez JL, Hernández-Rivas JM. Quijada-Álamo M, et al. Among authors: alonso perez v. Blood Cancer J. 2021 Jul 9;11(7):127. doi: 10.1038/s41408-021-00520-5. Blood Cancer J. 2021. PMID: 34244476 Free PMC article.
Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of pediatric leukemia initiation.
Boudia F, Baille M, Babin L, Aid Z, Robert E, Riviere J, Galant K, Alonso-Pérez V, Anselmi L, Arkoun B, Abermil N, Marzac C, Bertuccio SN, Regnault de Premesnil A, Lopez CK, Eeckhoutte A, Naimo A, Leite B, Catelain C, Metereau C, Gonin P, Gaspar N, Schwaller J, Bernard OA, Raslova H, Gaudry M, Marchais A, Lapillonne H, Petit A, Pflumio F, Arcangeli ML, Brunet E, Mercher T. Boudia F, et al. Among authors: alonso perez v. Blood. 2024 Dec 10:blood.2024024505. doi: 10.1182/blood.2024024505. Online ahead of print. Blood. 2024. PMID: 39656971
Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia.
Alonso-Pérez V, Galant K, Boudia F, Robert E, Aid Z, Renou L, Barroca V, Devanand S, Babin L, Rouiller-Fabre V, Moison D, Busso D, Piton G, Metereau C, Abermil N, Ballerini P, Hirsch P, Haddad R, Martinovic J, Petit A, Lapillonne H, Brunet E, Mercher T, Pflumio F. Alonso-Pérez V, et al. Mol Cancer. 2024 Sep 20;23(1):204. doi: 10.1186/s12943-024-02110-y. Mol Cancer. 2024. PMID: 39304903 Free PMC article.
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Quijada-Álamo M, Hernández-Sánchez M, Alonso-Pérez V, Rodríguez-Vicente AE, García-Tuñón I, Martín-Izquierdo M, Hernández-Sánchez JM, Herrero AB, Bastida JM, San Segundo L, Gruber M, García JL, Yin S, Ten Hacken E, Benito R, Ordóñez JL, Wu CJ, Hernández-Rivas JM. Quijada-Álamo M, et al. Among authors: alonso perez v. Leukemia. 2020 Jun;34(6):1599-1612. doi: 10.1038/s41375-020-0714-3. Epub 2020 Jan 23. Leukemia. 2020. PMID: 31974435 Free PMC article.